Seaport Therapeutics
Seaport Therapeutics raises $225M Series C at $1.2B valuation
Quick Facts
Seaport Therapeutics: Series C Funding Round
Seaport Therapeutics has successfully raised $225M in Series C funding, reaching a valuation of $1.2B.
Company Overview
Neuropsychiatric disease treatments
Funding Details
The Series C round was led by Fidelity, with participation from T. Rowe Price.
Company Information
- Headquarters: Boston, MA
- Founded: 2020
- Employees: 100+
- Category: Biotech
Investment
Seaport Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
